Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT03740165
- ENGOT-OV43, MK-7339-001, 2018-001973-25, 194619, ENGOT 001, CTA ID:CT1145
Trial sponsor
Merck
Scientific Title
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC)